ArticleHealth science reports2026
Prevalence and Predictors of Substance Use Disorder Due to Gabapentinoids in Patients With Chronic Non-Cancer Pain: A Cross-Sectional Study.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: The increase in the use of gabapentinoids in the treatment of patients with chronic non-cancer pain (CNCP) has drawn attention to the possibility of substance use disorder (SUD) due to gabapentinoids. Systematic literature reviews have provided evidence of the risk of SUD due to gabapentinoids within substance-using populations. Despite concerns, prescription rates of gabapentinoids continue to increase in many countries, such as the USA, the UK, and Germany. Gabapentinoids are frequently prescribed off-label for chronic pain regardless of neuropathic pain diagnosis, increasing the risk for problematic use. A recent literature review suggests that there is a potential for SUDs in CNCP, but robust data focusing specifically on this population is lacking. The present study aims to address this by investigating SUD due to gabapentinoids in a cohort of patients with CNCP. Methods: This study employs an anonymous, self-reported questionnaire-based cross-sectional design. It was conducted among CNCP patients in Results: The data revealed a prevalence of 26.9% ( Conclusion: The results suggest a relevant risk for SUDs due to gabapentinoids in CNCP patients. Special care should be taken when prescribing gabapentinoids to patients with CNCP. Male sex as a predictor of SUD due to gabapentinoids should be further investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.